COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01097083
Recruitment Status : Terminated
First Posted : April 1, 2010
Last Update Posted : January 14, 2014
Information provided by:
National University Hospital, Singapore

Brief Summary:
The hypothesis of this study is that the median time to progression in the experimental arm is 2 months as compared to the placebo arm of 1.4 months

Condition or disease Intervention/treatment Phase
Carcinoma Therapy Drug: Coriolus Versicolor Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy
Study Start Date : April 2010
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2013

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The diagnosis of HCC is made either by histological examination of tumor tissue or imaging evidence of a typical space-occupying lesion in the liver together with a serum AFP concentration of above 500 ng/ml (normal value, 10 ng/ml) in a known carrier of hepatitis B or C, or AFP above 400 ng/ml in non Hepatitis B or C carrier.

  • Patients with unresectable HCC that is not amenable to liver transplantation nor local ablative technique and who are not suitable for any conventional systemic therapy (including sorafenib and chemotherapy).
  • Patients with Child-Pugh Class C liver cirrhosis (Child-Pugh Scores of 10-15 points). Patients with Child-Pugh Class A or B liver cirrhosis who are not eligible for conventional therapy or other clinical trials or who refuse conventional therapy are included
  • Life Expectancy of at least 12 weeks
  • All patients should have anti-HBc antibodies tested if HBs Ag is negative. If anti-HBc is positive, HBV DNA detection should be performed to determine viral load. An undetectable Hep B DNA level (DNA levels < 12 IU/ml) in the presence of a positive Hep B core total antibody would indicate no active hepatitis infection and the subject would still be eligible for this trial.
  • Age >21 years.
  • Performance status ECOG 0 - 2
  • Patients must have normal organ and marrow function as defined below:

Absolute neutrophil count > 1.5 x 109/L Platelets > 50 x 109/L Haemoglobin > 9.0g/dl Total bilirubin < 51umol/L (3 mg /dL) AST (SGOT)/ALT (SGPT) < 5 X institutional ULN Creatinine < 1.5 ULN INR <1.7 or prothrombin time (PT) <4 seconds above ULN

  • Patients who have not received any local or systemic treatment in the last 4 weeks.
  • Measurable disease according to RECIST
  • Ability to understand and the willingness to sign a written informed consent document.
  • Ability to swallow oral medication
  • The effects of C versicolor on the developing human fetus are unknown. For this reason, woman of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Exclusion Criteria:

  • Patients with a history of prior malignancy that is distinct in site and histology from HCC except non-melanoma skin cancer. Any cancer curatively treated more than 3 years prior to entry is permitted.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, intractable ascites that could not be controlled by medical therapy
  • Prior use of C versicolor or Yunzhi for HCC
  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Patients who are using other chinese herbal therapies concurrently or on any other investigation agents for treatment of their cancer
  • Known of history of allergic reactions attributed to compounds of similar chemical or biologic composition used in the study.
  • Presence of active hepatitis B/C flare.
  • Known history of Human Immunodeficiency Virus (HIV) Infection
  • Gastrointestinal disease which could affect the absorption or pharmacokinetics of the study drug as determined by investigator
  • Psychiatric illness/social situations that would limit compliance with study requirements. Patients with severe depression or psychiatric disorders will be excluded.
  • Known alcohol and/or substance abuser that may interfere with the subject's participation in the study or evaluation of study results.
  • Pregnancy or breast-feeding subjects. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the 14 days prior to study enrollment and must be willing to use adequate contraception
  • Patients suffering from autoimmune disease, patients on concomitant long-term immunosuppressant therapy and those scheduled to receive bone marrow transplants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01097083

Layout table for location information
National University Hospital
Singapore, Singapore, 119074
Singapore General Hospital
Singapore, Singapore, 169608
National Cancer Centre
Singapore, Singapore, 169610
Sponsors and Collaborators
National University Hospital, Singapore
Layout table for investigator information
Principal Investigator: Wei Peng Yong, MRCP, MB ChB' National University Hospital, Singapore
Principal Investigator: Choo Su Pin, BMBS, MRCP, M Med National Cancer Centre
Principal Investigator: Tan Chee Kiat, MBBS, FRCP, FAMS Singapore General Hospital
Layout table for additonal information Identifier: NCT01097083    
Other Study ID Numbers: 3
First Posted: April 1, 2010    Key Record Dates
Last Update Posted: January 14, 2014
Last Verified: January 2014
Keywords provided by National University Hospital, Singapore:
Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma
Patients who are unfit for standard therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases